Doctors Caterina Oneto, and Paul Feuerstadt discussed

the Management of C. difficile Infections. The new guidelines released by

IDSA and SHEA this June along with the new treatments on the horizon were also a

topic of conversation.

Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 10% of the population reports a penicillin allergy but 1% of the whole population is truly allergic. People with a penicillin allergy on their medical record are not given penicillin, and may not be given any beta-lactam antibiotics because of concern that the allergy is shared across the antibiotic class. Instead, the antibiotics prescribed may be broader-spectrum. Broad-spectrum antibiotics may be as effective, but they often have more side effects and toxicities, such as increased risk of developing infections like C. diff (Clostridioides difficile, formerly called Clostridium difficile) or methicillin-resistant Staphylococcus aureus (MRSA).

Our guests Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS, Clinical Professor, University of Georgia College of Pharmacy and

Bruce M. Jones, Pharm.D., BCPS, Adjunct Clinical Associate Professor for the University of Georgia College of Pharmacy will join us to discuss antibiotics, the different types, diagnostics, diagnosis, and the Impact of Penicillin Allergy on a C. difficile Infection.

Join us with our guests from GoodNature, a Seres Therapeutics program; April Garcia, Site Manager of GoodNature Irvine California, and two GoodNature donors who will share their experiences. They will discuss the who, what, and how in donating poop to potentially support C. diff patients. With microbiome therapeutics on the forefront, it will be an educational discussion.

Join Us With our guest, Sahil Khanna, M.B.B.S., M.S. as we discuss the exciting times

of Microbiome Restoration For C. difficile infections and how we are almost

there! Dr. Khanna will be introducing the gut microbiome, the research, development, and importance of the microbiome in our health along with the microbiome therapeutics in clinical trials with validated safety and efficacy.

Join us with our guest; Ken Blount PhD, CSO Rebiotix Inc, a Ferring Company and VP Microbiome Research Ferring - as Dr. Blount introduces the gut microbiome. There is so much to learn about this cutting edge science, along with a discussion about the recurrence of a

C. difficile infection , and how clinical trials work.. The gut microbiome has a direct connection to our health and Dr. Blount will be shining some light on this educational topic

Have your mobile devices or a pen and notebook ready as we learn more about the gut microbiome,

C. difficile infections, clinical trials, and much more!

Approximately 10% of all U.S. patients report having an allergic reaction to a penicillin class antibiotic in their past. 10% of the population reports a penicillin allergy but 1% of the whole population is truly allergic. People with a penicillin allergy on their medical record are not given penicillin, and may not be given any beta-lactam antibiotics because of concern that the allergy is shared across the antibiotic class. Instead, the antibiotics prescribed may be broader-spectrum. Broad-spectrum antibiotics may be as effective, but they often have more side effects and toxicities, such as increased risk of developing infections like C. diff (Clostridioides difficile, formerly called Clostridium difficile) or methicillin-resistant Staphylococcus aureus (MRSA).

Our guests Christopher M. Bland, Pharm.D., FCCP, FIDSA, BCPS, Clinical Professor, University of Georgia College of Pharmacy and

Bruce M. Jones, Pharm.D., BCPS, Adjunct Clinical Associate Professor for the University of Georgia College of Pharmacy will join us to discuss antibiotics, the different types, diagnostics, diagnosis, and the Impact of Penicillin Allergy on a C. difficile Infection.

With microbiome therapeutics on the forefront, it will be an educational discussion with our guests: Jason Goldsmith, Donor Medical & Analytical Sciences, Elisha Ott, Director, Donor Operations, and Jennie Starr, Associate Director, Donor Recruitment.

Each guest will be sharing the information about the donor process, and the who, what, and how in donating poop for a good cause.

Niranjan Tex Kissoon , MD Mark Ansermino, MD and Matthew Wiens, MD

join us to discuss the multi-levels of Sepsis,. and educate us on the What, How, and Global Burden of Sepsis.

The Global Burden of Disease Sepsis Report published in January 2020 estimated that 49 million patients suffer sepsis every year, with 11 million of those dying. This burden is significantly higher than the number of lives lost to cancer or coronary disease. Sepsis can affect anyone as a consequence of infection, but globally young children suffer most.

sepsis remains one of the most common and least-recognized illnesses in both the developed and developing world. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, disability and death, especially if not recognized early and treated promptly.

September has been designated Sepsis Awareness Month and September 13th is Sepsis Awareness Day.

For more information please visit: https://www.global-sepsis-alliance.org and https://www.sepsis.org

Join Nancy C. Caralla and Kevin Hersh as we discuss the chapters and passion behind the newly published book, Managing a C. difficile Infection: For Patients, Families, and Caregivers.

Niranjan Tex Kissoon , MD Mark Ansermino, MD and Matthew Wiens, MD

join us to discuss the multi-levels of Sepsis,. and educate us on the What, How, and Global Burden of Sepsis.

The Global Burden of Disease Sepsis Report published in January 2020 estimated that 49 million patients suffer sepsis every year, with 11 million of those dying. This burden is significantly higher than the number of lives lost to cancer or coronary disease. Sepsis can affect anyone as a consequence of infection, but globally young children suffer most.

sepsis remains one of the most common and least-recognized illnesses in both the developed and developing world. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multiple organ failure, disability and death, especially if not recognized early and treated promptly.

September has been designated Sepsis Awareness Month and September 13th is Sepsis Awareness Day.

For more information please visit: https://www.global-sepsis-alliance.org and https://www.sepsis.org